INKT
MiNK Therapeutics, Inc. NASDAQ Listed Oct 15, 2021$11.01
Mkt Cap $54.7M
52w Low $6.34
6.7% of range
52w High $76.00
50d MA $11.03
200d MA $12.78
P/E (TTM)
-4.0x
EV/EBITDA
1081.4x
P/B
—
Debt/Equity
-0.4x
ROE
87.8%
P/FCF
-0.0x
RSI (14)
—
ATR (14)
—
Beta
0.35
50d MA
$11.03
200d MA
$12.78
Avg Volume
307.2K
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
CIK (SEC)
Phone
212 994 8250
149 Fifth Avenue · New York City, NY 10010 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | AMC | -0.68 | -0.52 | +23.5% | 9.57 | -0.3% | -1.1% | +3.0% | -3.4% | -6.3% | -2.9% | — |
| Nov 14, 2025 | AMC | -0.86 | -0.65 | +24.4% | 12.75 | +1.2% | -5.9% | -5.7% | -2.6% | -1.3% | -2.9% | — |
| Aug 14, 2025 | AMC | -0.55 | -1.06 | -92.7% | 15.32 | +14.2% | -2.7% | -1.9% | +0.5% | -1.6% | +3.3% | — |
| May 15, 2025 | AMC | -0.61 | -0.70 | -14.8% | 7.18 | +0.0% | +5.0% | +0.8% | -5.1% | +6.8% | -7.8% | — |
| Mar 18, 2025 | AMC | -0.50 | -0.62 | -24.0% | 8.24 | -5.3% | -3.9% | +6.2% | +8.2% | -5.8% | +0.0% | — |
| Nov 14, 2024 | AMC | -0.80 | -0.50 | +37.5% | 7.50 | +3.7% | +0.5% | -7.8% | -1.2% | +2.6% | -2.1% | — |
| Aug 13, 2024 | AMC | -1.00 | -0.70 | +30.0% | 8.49 | +2.7% | -1.1% | -2.3% | -1.3% | +3.6% | -1.1% | — |
| May 14, 2024 | AMC | -1.60 | -1.10 | +31.2% | 11.20 | -2.7% | -7.1% | +0.0% | -2.9% | +0.0% | -2.0% | — |
| Mar 21, 2024 | AMC | -1.50 | -1.60 | -6.7% | 8.90 | -2.1% | -2.2% | +5.5% | +2.2% | -3.0% | -0.2% | — |
| Nov 9, 2023 | AMC | -1.80 | -1.50 | +16.7% | 11.10 | -2.7% | -5.4% | -13.3% | +4.4% | +7.4% | -3.2% | — |
| Aug 10, 2023 | AMC | -1.90 | -1.80 | +5.3% | 19.20 | -7.3% | -4.7% | -1.1% | -5.5% | +1.8% | -4.0% | — |
| May 11, 2023 | AMC | -2.40 | -1.70 | +29.2% | 16.20 | +8.6% | +6.2% | -1.7% | -0.6% | +7.1% | -4.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.53 | $11.77 | +11.8% | +0.4% | +1.1% | +7.0% | +1.4% | -3.9% |
| Aug 15 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $15.32 | $17.49 | +14.2% | -2.7% | -1.9% | +0.5% | -1.6% | +3.3% |
| Jul 15 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $40.61 | $32.90 | -19.0% | -31.0% | -17.5% | +0.6% | -12.6% | -2.5% |
| Jul 14 | William Blair | Downgrade | Outperform → Market Perform | — | $64.17 | $42.01 | -34.5% | -36.7% | -31.0% | -17.5% | +0.6% | -12.6% |
| Mar 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.52 | $9.22 | +8.2% | -3.3% | -3.9% | +6.2% | +8.2% | -5.8% |
| Feb 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.65 | $10.32 | -3.1% | -9.3% | -3.5% | -2.4% | -1.6% | -1.8% |
| Nov 15 | Baird | Maintains | Outperform → Outperform | — | $7.50 | $7.78 | +3.7% | +0.5% | -7.8% | -1.2% | +2.6% | -2.1% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.50 | $7.78 | +3.7% | +0.5% | -7.8% | -1.2% | +2.6% | -2.1% |
| Oct 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.78 | $6.02 | -11.2% | -0.1% | -1.0% | +0.1% | +1.3% | -2.2% |
| Aug 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.35 | $8.59 | +2.9% | +1.7% | -1.1% | -2.3% | -1.3% | +3.6% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.80 | $9.70 | -1.0% | +14.3% | -7.1% | +0.0% | -2.9% | +0.0% |
| Mar 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.96 | $9.10 | +1.6% | -0.7% | -2.2% | +5.5% | +2.2% | -3.0% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.00 | $18.30 | +1.7% | +6.7% | -4.7% | -1.1% | -5.5% | +1.8% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.20 | $17.60 | +8.6% | +6.2% | -1.7% | -0.6% | +7.1% | -4.4% |
| Apr 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.20 | $20.20 | -4.7% | -3.3% | -2.0% | +4.5% | +2.9% | -2.8% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.42 | $20.60 | +0.9% | +2.4% | -3.8% | +0.0% | +0.0% | +5.0% |
| Mar 22 | Evercore ISI | Maintains | Outperform → Outperform | — | $20.42 | $20.60 | +0.9% | +2.4% | -3.8% | +0.0% | +0.0% | +5.0% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.20 | $13.60 | +3.0% | +16.7% | +9.1% | +1.8% | +98.8% | -4.4% |
| Jan 24 | B. Riley Securities | Maintains | Buy → Buy | — | $31.20 | $30.00 | -3.8% | -9.6% | +8.5% | +1.0% | -6.8% | +0.3% |
| Nov 9 | Evercore ISI | Maintains | Outperform → Outperform | — | $189.60 | $202.90 | +7.0% | +4.4% | -4.0% | +5.4% | -18.1% | +6.3% |
| Nov 9 | William Blair | Maintains | Outperform → Outperform | — | $189.60 | $202.90 | +7.0% | +4.4% | -4.0% | +5.4% | -18.1% | +6.3% |
| Nov 9 | Baird | Maintains | Outperform → Outperform | — | $189.60 | $202.90 | +7.0% | +4.4% | -4.0% | +5.4% | -18.1% | +6.3% |
No insider trades available.
8-K
Unknown — 8-K Filing
Inkt is pivoting toward auto-immune/inflammatory diseases with non-dilutive partnerships, potentially reducing capital needs and accelerating clinical progress without shareholder dilution.
Mar 31
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
I cannot provide meaningful analysis because the filing summary contains only boilerplate language about signature authority with no substantive information about INKT's business, financial condition, or material events.
Mar 27
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Chief executive officer departure signals potential leadership uncertainty at INKT, which could pressure the stock until a successor is named and a strategic direction is clarified.
Mar 19
Data updated apr 25, 2026 3:38pm
· Source: massive.com